NCT05018338: Brain-Shift Monitoring Using 3D Scanning

NCT05018338
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 6 Years and older (Child, Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be scheduled for a craniotomy at St. David’s North Austin Medical Center
Exclusions: 
https://ClinicalTrials.gov/show/NCT05018338

Comments are closed.

Up ↑